These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 8395791)
1. The Pathogenesis and Diagnosis of Apostolopoulou A; Fishman JA J Fungi (Basel); 2022 Nov; 8(11):. PubMed ID: 36354934 [No Abstract] [Full Text] [Related]
2. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Rodriguez M; Fishman JA Clin Microbiol Rev; 2004 Oct; 17(4):770-82, table of contents. PubMed ID: 15489347 [TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of recombinant Pneumocystis carinii topoisomerase I: differential interactions with human topoisomerase I poisons and pentamidine. van Dross RT; Sanders MM Antimicrob Agents Chemother; 2002 Jul; 46(7):2145-54. PubMed ID: 12069967 [TBL] [Abstract][Full Text] [Related]
4. Treatment of infection due to Pneumocystis carinii. Fishman JA Antimicrob Agents Chemother; 1998 Jun; 42(6):1309-14. PubMed ID: 9624465 [No Abstract] [Full Text] [Related]
5. Prevention of infection due to Pneumocystis carinii. Fishman JA Antimicrob Agents Chemother; 1998 May; 42(5):995-1004. PubMed ID: 9593116 [No Abstract] [Full Text] [Related]
6. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents. Cushion MT; Chen F; Kloepfer N Antimicrob Agents Chemother; 1997 Feb; 41(2):379-84. PubMed ID: 9021195 [TBL] [Abstract][Full Text] [Related]
7. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs. Walzer PD; Runck J; Steele P; White M; Linke MJ; Sidman CL Antimicrob Agents Chemother; 1997 Feb; 41(2):251-8. PubMed ID: 9021175 [TBL] [Abstract][Full Text] [Related]
8. Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium. Chio LC; Bolyard LA; Nasr M; Queener SF Antimicrob Agents Chemother; 1996 Mar; 40(3):727-33. PubMed ID: 8851601 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. Bartlett MS; Shaw M; Navaran P; Smith JW; Queener SF Antimicrob Agents Chemother; 1995 Nov; 39(11):2436-41. PubMed ID: 8585722 [TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent topoisomerase II-inhibiting drugs. Joel SP; Slevin ML Cancer Chemother Pharmacol; 1994; 34 Suppl():S84-8. PubMed ID: 8070033 [TBL] [Abstract][Full Text] [Related]
11. Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis. Séguy N; Polonelli L; Dei-Cas E; Cailliez JC FEMS Immunol Med Microbiol; 1998 Sep; 22(1-2):145-9. PubMed ID: 9792073 [TBL] [Abstract][Full Text] [Related]
12. Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model. Fishman JA; Queener SF; Roth RS; Bartlett MS Antimicrob Agents Chemother; 1993 Jul; 37(7):1543-6. PubMed ID: 8395791 [TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of topoisomerase inhibitors against Pneumocystis carinii. Cirioni O; Giacometti A; Quarta M; Scalise G J Antimicrob Chemother; 1997 Oct; 40(4):583-6. PubMed ID: 9372430 [TBL] [Abstract][Full Text] [Related]
14. Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo. Walzer PD; Ashbaugh A; Collins M; Cushion MT J Infect Dis; 2001 Nov; 184(10):1355-7. PubMed ID: 11679930 [TBL] [Abstract][Full Text] [Related]
15. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). Rappa G; Lorico A; Sartorelli AC Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186 [TBL] [Abstract][Full Text] [Related]